E2F-2 Antibody (TFE22): sc-56664
- E2F-2 Antibody (TFE22) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against full length E2F-2 of human origin
- recommended for detection of E2F-2 of mouse, rat and human origin by WB, IP, IF and ELISA
- See E2F-2 (TFE-25): sc-9967 for E2F-2 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for E2F-2 Antibody (TFE22) for WB applications. These reagents are now offered in bundles with E2F-2 Antibody (TFE22) (see ordering information below).
E2F-2 Antibody (TFE22) is a mouse monoclonal IgG1 antibody that recognizes E2F-2 in mouse, rat, and human samples through western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). E2F-2 plays a crucial role in regulating the cell cycle, particularly in the transition from G1 to S phase, by controlling the expression of genes necessary for DNA synthesis and cell proliferation. E2F-2 regulation is vital for maintaining proper cell growth and division, and dysregulation can lead to uncontrolled cell proliferation, contributing to tumorigenesis. E2F-2 is part of a larger family of E2F transcription factors, which interact with retinoblastoma protein (Rb) to form a transcriptional regulatory complex essential for precise cell cycle progression control. Formation of heterodimers with DP-1 protein enhances E2F-2 transcriptional activity, enabling effective regulation of target genes involved in cell cycle control. Anti-E2F-2 antibody (TFE22) enables researchers to gain insights into cell cycle regulation mechanisms and E2F-2′s potential implications in cancer biology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
E2F-2 Antibody (TFE22) References:
- Co-expression of E2F-2 enhances the p53 anti-cancer effect in human glioma cells. | Mitlianga, PG., et al. 2001. Int J Oncol. 18: 343-7. PMID: 11172602
- Deregulated E2f-2 underlies cell cycle and maturation defects in retinoblastoma null erythroblasts. | Dirlam, A., et al. 2007. Mol Cell Biol. 27: 8713-28. PMID: 17923680
- Increased E2F2 predicts poor prognosis in patients with HCC based on TCGA data. | Zeng, Z., et al. 2020. BMC Cancer. 20: 1037. PMID: 33115417
- CircCUL2 suppresses retinoblastoma cells by regulating miR-214-5p/E2F2 Axis. | Zhang, H., et al. 2022. Anticancer Drugs. 33: e218-e227. PMID: 34387590
- Protective Role of lncRNA TTN-AS1 in Sepsis-Induced Myocardial Injury Via miR-29a/E2F2 Axis. | Pei, X., et al. 2022. Cardiovasc Drugs Ther. 36: 399-412. PMID: 34519914
- ZNF750 exerted its Antitumor Action in Oral Squamous Cell Carcinoma by regulating E2F2. | Yang, HL., et al. 2021. J Cancer. 12: 7266-7276. PMID: 35003347
- Decreased E2F2 Expression Correlates with Poor Prognosis and Immune Infiltrates in Patients with Colorectal Cancer. | Shang, Y., et al. 2022. J Cancer. 13: 653-668. PMID: 35069909
- Silencing of circ-CDK14 suppresses osteosarcoma progression through the miR-198/E2F2 axis. | Liu, J., et al. 2022. Exp Cell Res. 414: 113082. PMID: 35218724
- E2F2 promotes lung adenocarcinoma progression through B-Myb- and FOXM1-facilitated core transcription regulatory circuitry. | Du, K., et al. 2022. Int J Biol Sci. 18: 4151-4170. PMID: 35844795
- Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F. | Ivey-Hoyle, M., et al. 1993. Mol Cell Biol. 13: 7802-12. PMID: 8246995
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
E2F-2 Antibody (TFE22) | sc-56664 | 200 µg/ml | $316.00 | |||
E2F-2 Antibody (TFE22): m-IgG Fc BP-HRP Bundle | sc-537110 | 200 µg Ab; 10 µg BP | $354.00 | |||
E2F-2 Antibody (TFE22): m-IgGκ BP-HRP Bundle | sc-534302 | 200 µg Ab; 40 µg BP | $354.00 |